We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gene Logic Releases ASCENTA® System 2.0
Product News

Gene Logic Releases ASCENTA® System 2.0

Gene Logic Releases ASCENTA® System 2.0
Product News

Gene Logic Releases ASCENTA® System 2.0


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Gene Logic Releases ASCENTA® System 2.0"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Gene Logic Inc. has announced the release of ASCENTA® System 2.0, a version of its existing web-based product for gene and biomarker discovery and validation.

Version 2.0 is designed to offer gene expression information and progressive tools to help researchers identify key genes and biological pathways which possess distinctive expression characteristics and disease-related expression patterns.

The ASCENTA System includes Gene Logic's marker/X™ Tool, pathwayPrioritizer™ Tool, Diff/X™ Summary Tables and human gene expression information, including inflammation content for multiple sclerosis and inflammatory bowel disease, and central nervous system content for Parkinson's disease.

Dennis Rossi, senior vice president and general manager, Genomics for Gene Logic, said, “The ASCENTA System 2.0 provides our customers with a suite of new tools and functionalities that are unique in the marketplace.”

“This new version is a necessary evolution to meet the complex and changing needs of our customers.”

“Our goal is to furnish our customers with new tools to better understand the regulation of key biological pathways in human disease and quickly identify genes with unique and distinguishing expression patterns in human tissues.”

“We envision that dynamic application of these new tools to our enhanced gene expression data will quicken the path to drug target, biomarker and pathway discovery.”

Advertisement